Support Line: 0800 002 9002
General Enquiries: 01223 870008

Results for "cabozantinib"

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in patients with advanced renal cell carcinoma and bone metastases, according to a subgroup analysis of a pivotal clinical trial. Data from that trial, called METEOR (Metastatic Renal Cell...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

CABOSUN trail shines for Cabozantinib

New CABOSUN Data Show Better PFS With Cabozantinib in mRCC Read the full article HERE Updated results from the phase II CABOSUN trial showed cabozantinib significantly prolonged progression-free survival (PFS) per independent review committee compared with sunitinib...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Hopes for Cabozantinib NICE recommendation

Kidney Cancer UK is very disappointed to hear that at the midpoint of the Single Technology Appraisal (STA) of cabozantinib, NICE is considering NOT recommending its use within the NHS in England and Wales. Having a variety of targeted therapy options is vital for...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

cabozantinib, new first line treatment for kidney cancer

Once-daily tablet, CABOMETYX®▼(cabozantinib), approved by NICE as a first-line treatment for adult patients with Advanced Renal Cell Carcinoma (RCC) with intermediate or poor risk per the International Metastatic Renal Cell Carcinoma Database (IMDC) criteria The UK...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Cabozantinib Effective in Real-World Analysis for Relapsed Mrcc

Cabozantinib is a safe and effective treatment option for patients with relapsed renal cell carcinoma (RCC) in every clinical practice, according to a study published in Clinical Genitourinary Cancer. The phase 3 METEOR study previously demonstrated that cabozantinib...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Cabozantinib Yields Similar QoL Outcomes to Everolimus in RCC

Patients with advanced renal cell carcinoma had an improved time to deterioration (TTD) and similar quality of life (QoL) after treatment with cabozantinib compared with everolimus, according to a study published in the Journal of Clinical Oncology.1 The phase 3...

Cabozantinib

Cabozantinib

Cabozantinib is used to treat renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Cabozantinib is given in tablet form and is Available in all of UK. The combination therapy of Cabozantinib...

SMC approve of nivolumab and cabozantinib

SMC approve of nivolumab and cabozantinib

Statement from Kidney Cancer Scotland on the news of the SMC’s approval of nivolumab and cabozantinib for late stage kidney cancer patients in Scotland. The news today that two important drugs for kidney cancer have been approved for patients in advanced stages of the...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

The Evolving Management of Advanced Renal Cell Carcinoma

A review from the American website Urototady.com of Dr. Rana R. McKay State-of-the-Art lecture providing a comprehensive presentation of the evolving management of advanced renal cell carcinoma (RCC) at the SUO2017 (Society of Urologic Oncology) Conference. You may...

CheckMate data support 1st nivo–cabo in advanced RCC

CheckMate data support 1st nivo–cabo in advanced RCC

CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma (RCC) report less decline in health-related quality of life (HRQoL) during treatment than those given...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Cabo/atezo phase 3 combo RCC trial launched

The phase 3 CONTACT-03 trial is exploring the combination of the multikinase inhibitor and immunotherapy agent in patients with renal cell carcinoma after exposure to an immune-checkpoint inhibitor The pivotal phase 3 CONTACT-03 trial has been launched with the goal...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Tivozanib Shows Superior Safety Profile Across TKIs in mRCC

For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies for mRCC. Cabozantinib, sunitinib, pazopanib, and tivozanib show similar efficacy for the treatment of...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

EMA recommends two new kidney cancer drugs

Two new drugs for the treatment of adults with advanced kidney cancer are being recommended by the European Medicines Agency (EMA) for fast track approval across the EU. Cabozantinib (marketed as Cabometyx) and lenvatinib (marketed as Kisplyx) are being recommended...

Persist! Persist! Persist!

Persist! Persist! Persist!

A  special blog for Kidney Cancer Awareness Week 2023 by Richard Jetten I was 41 and running our own Spanish Tapas restaurant when one morning I noticed my wee had turned red, it looked just like Cherryade! Initially I dismissed this as a bad bottle of red wine from...

Kidney Cancer UK represents patients at NICE appraisals

Kidney Cancer UK represents patients at NICE appraisals

On the 10th May 2018 the National Institute for Care and Health Excellence (NICE) appraised two different drug treatments in two meetings. The first for nivolumab with ipilimumab combination, and the second for cabozantinib as first line drugs for intermediate and...

Cabo + nivo & ipi delays kidney cancer progression

Cabo + nivo & ipi delays kidney cancer progression

Adding cabozantinib (Cabometyx) to nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma (RCC), according to the primary analysis of the...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Cabo+Tecentriq combo shows promise in advanced ccRCC

Treatment with Cabometyx (cabozantinib) in combination with Tecentriq (atezolizumab) demonstrated promising clinical activity in patients with advanced clear cell renal cell carcinoma (ccRCC), according to results from the phase 1b COSMIC-021 study presented at the...

Cabozantinib Bests Everolimus in RCC with Bone Metastases

Drug combo hits targets in first-line RCC trial

Bristol Myers Squibb and Exelixis have announced that a late-stage study testing a combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) has hit its primary target of extending progression-free survival in certain patients with kidney cancer. The Phase III...

Kidney Cancer UK represents patients at NICE appraisals

Over 20 Years of Kidney Cancer UK

For the over 20 years Kidney Cancer UK has been a consistent, prominent and influential name working to support patients through the approval of drugs for kidney cancer patients, better treatments and a clear treatment pathway. No matter who the faces are behind the...

Support Line

OPEN 5 DAYS A WEEK

0800 002 9002

Kidney Cancer Information

Whether you are recently diagnosed, undergoing or completed treatment for kidney cancer, are a carer, a friend or family of a kidney cancer patient, Kidney Cancer UK is here for you .

For further support call our Support Line to talk to a member of our Health team on 0800 002 9002.